Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Norman Chang

Internal Medicine Fredericksburg, VA Medical Doctor

NPI 1629064605 CMS profile 300958

611 Jefferson Davis Hwy, Suite 201, Fredericksburg, VA 22401

Open in the dashboard

General payments

$8,247

372 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Norman Chang of Fredericksburg, VA is reported in the CMS Open Payments database as having received $8,247 across 372 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $172 7
2024 General $232 10
2023 General $409 20
2022 General $2,158 42
2021 General $1,277 67
2020 General $1,820 94
2019 General $2,179 132

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Norman Chang
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Norman Chang were reported at $172. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Norman Chang Internal Medicine median Middle half National median
2019 $2,179 $159 $48–$570 $163
2020 $1,820 $119 $33–$402 $114
2021 $1,277 $135 $37–$521 $132
2022 $2,158 $141 $42–$496 $149
2023 $409 $149 $45–$519 $160
2024 $232 $154 $47–$537 $164
2025 $172 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,200 1 payment
  2. Sanofi-Aventis U.S. LLC $730 26 payments
  3. Pfizer Inc. $612 44 payments
  4. Novo Nordisk Inc $447 34 payments
  5. AstraZeneca Pharmaceuticals LP $401 26 payments
  6. GlaxoSmithKline, LLC. $389 5 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $358 35 payments
  8. AbbVie, Inc. $322 17 payments
  9. Amgen Inc. $283 14 payments
  10. Organogenesis Inc. $256 6 payments
  11. Other $3,249 164 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,026 360 payments
  2. Consulting Fee $1,425 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $690 8 payments
  4. Education $106 2 payments
Products named General payments · program years 2019–2025
  1. SOLIQUA 100/33 $379 7 payments
  2. XIFAXAN $358 35 payments
  3. FARXIGA $351 22 payments
  4. Ozempic $314 21 payments
  5. RYBELSUS $223 13 payments
  6. Puraply $218 5 payments
  7. TOUJEO Endocrine & Metabolic Diseases $202 7 payments
  8. ELIQUIS $194 12 payments
  9. TRULANCE $179 13 payments
  10. TOUJEO Diabetes $175 6 payments
  11. Other $6,913 424 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 82 drugs

Part D claims

2,444

Median for Internal Medicine: 777

Drug cost

$282,649

Median for Internal Medicine: $73,373

Branded share of claims

20.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 36 $58,548
Mounjaro Tirzepatide Brand 38 $45,454
Eliquis Apixaban Brand 48 $29,066
Trulicity Dulaglutide Brand 18 $26,566
Ozempic Semaglutide Brand 22 $24,850
Myrbetriq Mirabegron Brand 23 $22,363
Januvia Sitagliptin Phosphate Brand 14 $20,060
Linzess Linaclotide Brand 11 $9,358
Janumet Sitagliptin Phos/Metformin Hcl Brand 13 $7,203
Olmesartan-Hydrochlorothiazide Olmesartan/Hydrochlorothiazide Brand 28 $2,687

The 10 drugs with the highest cost, of 82 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$172,992

Of which drugs: $109

Medicare patients

432

Average age 77

Services billed

2,756

223 women, 209 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 41%
Diabetes 36%
Atrial fibrillation 28%
Chronic kidney disease 28%
Heart failure 23%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 15 56 $50

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

372 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record